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Endophytic Aspergillus fumigatusTwo new oxanthrone C-glycosides, patientosides A (14) and B (15), together with three known ones (11–
13), were isolated from Rumex patientia. Their structures were identiﬁed on the basis of spectroscopic
methods. The absolute conﬁguration for 14 and 15were deduced by analysis of their CD spectra and com-
parison with those of known similar compounds. Compounds 11–15, and 14 known anthraquinones (1–
4, 6–10, 16–20) previously isolated from Rumex nepalensis, Rumex hastatus, and endophytic Aspergillus
fumigatus, respectively, as well as a commercially available compound rhein (5) were evaluated for their
inhibitory effects on IL-6 and extracellular matrix production in mesangial cells.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Diabetic nephropathy (DN) is a progressive kidney disease
caused by angiopathy of capillaries in the kidney glomeruli.
DN is also a major complication of diabetes and a leading cause
of end-stage renal disease (ESRD).1,2 Increasing clinical evidences
shows that chronic inﬂammation, overproduction of extracellu-
lar matrix and reactive oxygen species in renal cells were impli-
cated in the progression of DN. Therefore, research targeting on
these pathogenic factors may contribute to the intervention of
DN.
The genus Rumex (Polygonaceae) comprises approximately 200
species which were widely distributed in the world, and China has
26 species.3 Rumex plants contain anthraquinones,4–10 which
showed various pharmacological properties, such as antitumor,11
antimutagenicity,12 and antioxidant activities.7 As our continuous
study on the DN prevention and therapy.13,14 The root of Rumex
patientia was investigated which led to the isolation of two new
oxanthrone C-glycoside, patientosides A (14) and B (15), together
with three known ones (11–13) (Fig. 1). These ﬁve oxanthroneC-glycosides (11–15) and commercially available rhein (5), as well
as previously isolated anthraquinone derivatives from Rumex
nepalensis (1–4, 6–10), Rumex hastatus (1, 2, 6, 8, 9), and endo-
phytic Aspergillus fumigatus isolated from the leaves of Trifolium re-
pens (16–20) were evaluated for their potential on DN.
Compound 1415 was isolated16 as a yellow amorphous solid. Its
molecular formula was assigned as C22H24O10 by HR-EI-MS peak at
m/z 448.1362 ([M]+, calcd for 448.1369). The UV spectra of 14
showed maximum absorptions at 211, 252, 275, and 366 nm, char-
acteristic of a highly conjugated system.17 The IR absorptions indi-
cated the presence of hydroxyl (3441, 3425 cm1) and carbonyl
(1639 cm1) groups. The 1H NMR spectra showed two meta-cou-
pled aromatic proton spin systems: dH 6.73 (1H, br s, H-2), 7.23
(1H, br s, H-4), 7.07 (1H, d, J = 2.4 Hz, H-5), and 6.41 (1H, d,
J = 2.4 Hz, H-7). Analysis of the 13C NMR and DEPT spectrum of 14
showed 22 carbon resonances, including two methyls (one methyl
at dC 22.2 and onemethoxyl at dC 56.1), one oxymethylene (dC 63.1),
four aromatic methines, ﬁve sp3 oxymethines, and ten quaternary
carbons, of which one was carbonyl (dC 192.5). The 1H and 13C
NMR spectroscopic data of 14 (Table 1) were similar to those of
rumejaposide E,5 an oxanthrone C-glycoside, except for the pres-
ence of an additional methoxyl group (dC 56.1). Themethoxyl group
was located at C-6 by the HMBC correlations from protons (dH 3.91)
to C-6 (Fig. 2). The Cotton effects of 14 in the range of 195–400 nm
(Fig. 3) were similar to those of mayoside (10R) and opposite to
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Figure 1. The structure of compounds 1–20.
Table 1
1H and 13C NMR data of compound 14a and 15a in CD3COCD3
No. 14 15
dH (mult, J in Hz) dC dH (mult, J in Hz) dC
1 162.6 162.1
1a 114.8 114.7
2 6.73, br s 117.8 6.72, br s 117.6
3 147.2 148.0
4 7.23, br s 119.9 7.23, br s 118.7
4a 150.9 148.0
5 7.07, d, 2.4 106.2 6.95, d, 2.2 107.5
5a 146.0 148.4
6 167.0 166.4
7 6.41, d, 2.4 100.7 6.44, d, 2.2 100.6
8 164.9 165.4
8a 111.0 111.1
9 192.5 192.5
10 76.5 76.7
11 2.39, s 22.2 2.38, s 22.4
10 3.29, d, 9.5 84.6 2.26, d, 9.4 84.4
20 3.06, dd, 9.1, 9.1 72.7 3.13, m 72.6
30 3.35, overlap 79.2 3.35, m 79.2
40 2.93, m 71.6 2.93, m 71.6
50 2.99, m 81.1 2.95, d, 5.2 81.0
60 3.52, br d, 11.7 63.1 3.50, br d, 10.2 63.1
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Table 1 (continued)
No. 14 15
dH (mult, J in Hz) dC dH (mult, J in Hz) dC
3.36, overlap 3.40, m
OMe 3.91, s 56.1 3.92, s 56.1
1-OH 11.9, br s 11.9, br s
8-OH 12.2, br s 12.2, br s
a 1H NMR recorded in 500 MHz, 13C NMR recorded in 125 MHz.
Figure 3. The CD spectrum of compounds 14 and 15.
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Figure 2. The key HMBC correlations of compound 14.
Y. Yang et al. / Bioorg. Med. Chem. Lett. 23 (2013) 3905–3909 3907those of saroside (10S),18 indicating the 10R conﬁguration of 14.
Therefore, the structure of 14 was determined to be (10R)10-C-b-
glucopyranosyl-1,8-dihydroxy-3-methyl-6-methoxy-9(10H)-anth-
racenone, named patientoside A.
Compound 1519 was also isolated as a yellow amorphous solid,
and has the molecular formula of C22H24O10 deduced from its HR-
EI-MS (m/z 448.1363 ([M]+, calcd for 448.1369), which was theFigure 4. Inhibitory effect of the compounds on IL-6. ⁄P <0.05 versus normal glucose; #P
(4), chrysophanol-8-O-b-D-glucopyranoside (6), emodin-8-O-b-D-(6)-O-acetyl)glucopyra
(10), 1-O-methylemodin (16), questin (17), 1,2-seco-trypacidin (18), trypacidin (19), ansame as compound 14. The 1H and 13C NMR spectroscopic data
(Table 1) of compounds 14 and 15 were highly similar, except for
C-4a and C-5a, suggesting the difference of the conﬁguration at
C-10. The Cotton effects in the range of 195–400 nm of 15 are
opposite to those of patientoside A, which further conﬁrmed our
above conclusion. Thus, compound 15 was determined to be
(10S)10-C-b-glucopyranosyl-1,8-dihydroxy-3-methyl-6-methoxy-
9(10H)-anthracenone, named patientoside B.
The known compounds from R. patientiawere each identiﬁed as
rumejaposide E (11),5 cassialoin (12),20 and rumejaposide I (13)20
by comparison their spectroscopic data and the Cotton effects with
those in the literatures.
Rumex plants were traditionally used for the treatment of renal
and urogenital disorders, the isolated compounds from Rumex
plants and A. fumigatuswere therefore screened for their inhibition
on the secretion of IL-6 and overproduction of extracellular matrix
production in high-glucose-induced mesangial cells. The results
showed that compounds 1–4, 6–9, 14–20 could signiﬁcantly inhi-
bit the secretion of IL-6 at 10 lM (Fig. 4),21–24 whereas, rhein is
inactive even at the concentration of 35 lM (data not shown). In
contrast, rhein has been proved effective in the treatment of exper-
imental DN, but it is active in vitro assay at a relatively high con-
centration (88 lM).25 The difference of potency between rhein
and the isolates implied that the carboxylic acid group in the struc-
ture of rhein is unfavorable for keeping the activity, and these iso-
lates may be more potent than rhein against DN. The
overproduction of extracellular matrix production is implicated
in the pathogenic process of DN and chronic kidney diseases. Our
investigation on extracellular matrix production inhibition showed
that compounds 1–3, 9, 11, 14, 17–20 could signiﬁcantly decrease
collagen IV and ﬁbronectin production at 10 lM (Figs. 5 and 6). In
addition, cell viability assay26 showed that all the compounds are
not cytotoxic at 10 lM (data not shown). The above data suggested
that anthraquinone derivatives are of great value for anti-DN drug
optimization.<0.05 versus high glucose. chrysophanol (1), emodin (2), physcion (3), aloe-emodin
noside (7), emodin-8-O-b-D-glucopyranoside (8), nepalenside A (9), nepalenside B
d asperfumin (20). Rhein (5) was from a commercial source.
Figure 6. Inhibitory effect of the compounds on ﬁbronectin. ⁄P <0.05 versus normal glucose; #P <0.05 versus high glucose.
Figure 5. Inhibitory effect of the compounds on collagen IV. ⁄P <0.05 versus normal glucose; #P <0.05 versus high glucose.
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